BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28121221)

  • 1. The association between circulating tumor cells and Epstein-Barr virus activation in patients with nasopharyngeal carcinoma.
    He C; Huang X; Su X; Tang T; Zhang X; Ma J; Guo X; Lv X
    Cancer Biol Ther; 2017 Nov; 18(11):888-894. PubMed ID: 28121221
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Correlations among Circulating Tumor Cells, Epstein-Barr Virus Status, and Epidemiology in Patients with Nasopharyngeal Carcinoma.
    Dong L; Luo Y; Li Y; Qin W; Cheng Y; Liu J; Zhang Z; Wang Z; Li H; Li S; Zhou X; Cai Y
    Clin Lab; 2022 Oct; 68(10):. PubMed ID: 36250833
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical significance of circulating tumor cells and their expression of cyclooxygenase-2 in patients with nasopharyngeal carcinoma.
    Xie XQ; Luo Y; Ma XL; Li SS; Liu L; Zhang H; Li P; Wang F
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6951-6961. PubMed ID: 31486495
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating tumor cells with karyotyping as a novel biomarker for diagnosis and treatment of nasopharyngeal carcinoma.
    Zhang J; Shi H; Jiang T; Liu Z; Lin PP; Chen N
    BMC Cancer; 2018 Nov; 18(1):1133. PubMed ID: 30454007
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship of circulating tumor cells and Epstein-Barr virus DNA to progression-free survival and overall survival in metastatic nasopharyngeal carcinoma patients.
    You R; Liu YP; Lin M; Huang PY; Tang LQ; Zhang YN; Pan Y; Liu WL; Guo WB; Zou X; Zhao KM; Kang T; Liu LZ; Lin AH; Hong MH; Mai HQ; Zeng MS; Chen MY
    Int J Cancer; 2019 Nov; 145(10):2873-2883. PubMed ID: 31044420
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of plasma Epstein-Barr virus (EBV) DNA levels and serum EBV immunoglobulin A/virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma.
    Shao JY; Li YH; Gao HY; Wu QL; Cui NJ; Zhang L; Cheng G; Hu LF; Ernberg I; Zeng YX
    Cancer; 2004 Mar; 100(6):1162-70. PubMed ID: 15022282
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expression of VCA (viral capsid antigen) and EBNA1 (Epstein-Barr-virus-encoded nuclear antigen 1) genes of Epstein-Barr virus in Pichia pastoris and application of the products in a screening test for patients with nasopharyngeal carcinoma.
    Hu B; Hong G; Li Z; Xu J; Zhu Z; Li L
    Biotechnol Appl Biochem; 2007 May; 47(Pt 1):59-69. PubMed ID: 17129209
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved accuracy of detection of nasopharyngeal carcinoma by combined application of circulating Epstein-Barr virus DNA and anti-Epstein-Barr viral capsid antigen IgA antibody.
    Leung SF; Tam JS; Chan AT; Zee B; Chan LY; Huang DP; Van Hasselt A; Johnson PJ; Lo YM
    Clin Chem; 2004 Feb; 50(2):339-45. PubMed ID: 14684618
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association of Plasma Epstein-Barr Virus LMP1 and EBER1 with Circulating Tumor Cells and the Metastasis of Nasopharyngeal Carcinoma.
    Sun L; Wang Y; Shi J; Zhu W; Wang X
    Pathol Oncol Res; 2020 Jul; 26(3):1893-1901. PubMed ID: 31832991
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Loss of heterozygosity and its correlation with clinical outcome and Epstein-Barr virus infection in nasopharyngeal carcinoma.
    Shao JY; Huang XM; Yu XJ; Huang LX; Wu QL; Xia JC; Wang HY; Feng QS; Ren ZF; Ernberg I; Hu LF; Zeng YX
    Anticancer Res; 2001; 21(4B):3021-9. PubMed ID: 11712805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The interaction and mediation effects between the host genetic factors and Epstein-Barr virus VCA-IgA in the risk of nasopharyngeal carcinoma.
    Diao H; Xue WQ; Wang TM; Yang DW; Deng CM; Li DH; Zhang WL; Liao Y; Wu YX; Chen XY; Zhou T; Li XZ; Zhang PF; Zheng XH; Zhang SD; Hu YZ; Cao SM; Liu Q; Ye WM; He YQ; Jia WH
    J Med Virol; 2023 Nov; 95(11):e29224. PubMed ID: 37970759
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Single-assay combination of Epstein-Barr Virus (EBV) EBNA1- and viral capsid antigen-p18-derived synthetic peptides for measuring anti-EBV immunoglobulin G (IgG) and IgA antibody levels in sera from nasopharyngeal carcinoma patients: options for field screening.
    Fachiroh J; Paramita DK; Hariwiyanto B; Harijadi A; Dahlia HL; Indrasari SR; Kusumo H; Zeng YS; Schouten T; Mubarika S; Middeldorp JM
    J Clin Microbiol; 2006 Apr; 44(4):1459-67. PubMed ID: 16597877
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Exosomal cyclophilin A as a novel noninvasive biomarker for Epstein-Barr virus associated nasopharyngeal carcinoma.
    Liu L; Zuo L; Yang J; Xin S; Zhang J; Zhou J; Li G; Tang J; Lu J
    Cancer Med; 2019 Jun; 8(6):3142-3151. PubMed ID: 31063269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus (EBV) latent membrane protein 1 induces interleukin-8 through the nuclear factor-kappa B signaling pathway in EBV-infected nasopharyngeal carcinoma cell line.
    Ren Q; Sato H; Murono S; Furukawa M; Yoshizaki T
    Laryngoscope; 2004 May; 114(5):855-9. PubMed ID: 15126743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Polymyositis/dermatomyositis and nasopharyngeal carcinoma: the Epstein-Barr virus connection?
    Chen DY; Chen YM; Lan JL; Chen HH; Hsieh CW; Wey SJ; Lu JJ
    J Clin Virol; 2010 Dec; 49(4):290-5. PubMed ID: 20934910
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Circulating Tumour Cells and Circulating Cell-Free Epstein-Barr Virus DNA in Patients with Nasopharyngeal Carcinoma Undergoing Radiotherapy.
    Vo JH; Nei WL; Hu M; Phyo WM; Wang F; Fong KW; Tan T; Soong YL; Cheah SL; Sommat K; Low H; Ling B; Ng J; Tan WL; Chan KS; Oon L; Ying JY; Tan MH
    Sci Rep; 2016 Dec; 6(1):13. PubMed ID: 28442757
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine CCL27 is a novel plasma biomarker for identification the nasopharyngeal carcinoma patients from the Epstein-Barr virus capsid antigen-specific IgA seropositive population.
    Mao MJ; Xue N; Wang XP; Chi PD; Liu YJ; Huang Q; Dai SQ; Liu WL
    BMC Cancer; 2018 Jan; 18(1):9. PubMed ID: 29295705
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel biomarkers of nasopharyngeal carcinoma metastasis risk identified by reverse phase protein array based tumor profiling with consideration of plasma Epstein-Barr virus DNA load.
    Xu T; Su B; Huang P; Wei W; Deng Y; Sehgal V; Wang D; Jiang J; Zhang G; Li A; Yang H; Claret FX
    Proteomics Clin Appl; 2017 May; 11(5-6):. PubMed ID: 27883284
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reactive nitrogen species-dependent DNA damage in EBV-associated nasopharyngeal carcinoma: the relation to STAT3 activation and EGFR expression.
    Ma N; Kawanishi M; Hiraku Y; Murata M; Huang GW; Huang Y; Luo DZ; Mo WG; Fukui Y; Kawanishi S
    Int J Cancer; 2008 Jun; 122(11):2517-25. PubMed ID: 18307254
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Analysis of Epstein-Barr viral DNA load, EBV-LMP2 specific cytotoxic T-lymphocytes and levels of CD4+CD25+ T cells in patients with nasopharyngeal carcinomas positive for IgA antibody to EBV viral capsid antigen.
    Mo WN; Tang AZ; Zhou L; Huang GW; Wang Z; Zeng Y
    Chin Med J (Engl); 2009 May; 122(10):1173-8. PubMed ID: 19493466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.